Related Experiment Videos
A 2-phase screening process for patients with Wegener's granulomatosis: a pilot study
Graciela S Alarcón1, Larry W Moreland, Michael J Sillers
1Division of Clinical Immunology and Rheumatology, Department of Medicine, 615 MEB, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
The Journal of Rheumatology
|December 17, 2003
Summary
This pilot study evaluated a two-phase screening for Wegener's granulomatosis (WG) in patients with persistent upper respiratory symptoms. One case of WG was detected, suggesting further research is needed.
Area of Science:
- Rheumatology
- Otolaryngology
- Internal Medicine
Background:
- Wegener's granulomatosis (WG), now known as granulomatosis with polyangiitis (GPA), is a rare autoimmune vasculitis.
- Persistent upper respiratory tract manifestations can be indicative of underlying systemic diseases like WG/GPA.
- Early diagnosis and treatment are crucial for managing WG/GPA and preventing severe complications.
Purpose of the Study:
- To assess the feasibility and effectiveness of a novel 2-phase screening protocol for detecting Wegener's granulomatosis (WG) in patients presenting with persistent upper respiratory symptoms.
- To determine the diagnostic yield of the proposed screening method in a pilot cohort.
Main Methods:
- A 2-phase screening process was developed and applied to a cohort of 28 patients with persistent upper respiratory tract manifestations.
- The screening involved [details of phase 1] and [details of phase 2] to identify potential WG cases.
Main Results:
- The screening protocol was tested on 28 patients.
- One patient was identified with Wegener's granulomatosis (WG).
Conclusions:
- The pilot study demonstrated that the 2-phase screening process can identify patients with Wegener's granulomatosis (WG) among those with persistent upper respiratory symptoms.
- A larger, multi-center study is warranted to validate these findings and establish the utility of this screening approach in clinical practice.